Abstract
The COVID-19 pandemic forced the scientific community and the pharmaceutical industry to develop new vaccines, in an attempt to reach herd immunity and stop the SARS-CoV-2 from spreading. However, to ensure vaccination among the general population, COVID-19 vaccine intention must be measured. So far, no studies have focused on rural residents in Latin America, which represent approximately 20% of the population of this geographical region. In this study, we present the validation of a self-developed questionnaire, which was validated in a pilot study with 40 Spanish-speaking Mexican rural residents in the state of Guerrero, Mexico. In this study, we describe the chronological validation of the questionnaire, including the assessment of its internal consistency and temporal reliability, which we measured with the Cronbach’s alpha and Spearman’s rank correlation coefficient, respectively. After the psychometrical analysis, we were able to validate a 20-item questionnaire, which intends to assess vaccine intention among the rural population. Aiming to develop a comprehensive policy and vaccination strategies, we hope this instrument provides valuable insight regarding COVID-19 vaccination willingness across rural communities in Mexico and Latin America. Finally, if we want to reach worldwide herd immunity, it is important to understand rural residents’ position towards COVID-19 vaccination.
Highlights
In December 2019, the World Health Organization (WHO) reported an outbreak of pneumonia associated with a severe acute respiratory distress syndrome (SARS) of unknown etiology in the City of Wuhan, China [1]
Each subsection was designed to measure different elements related to the COVID-19 vaccine, and what we were looking for is a high alpha for each section
These facts indicate that the Latin America (LATAM) region has been deeply affected by the COVID-19 pandemic and that vaccine intention in this geographical area needs to be assessed
Summary
In December 2019, the World Health Organization (WHO) reported an outbreak of pneumonia associated with a severe acute respiratory distress syndrome (SARS) of unknown etiology in the City of Wuhan, China [1]. The etiological agent was identified as a virus of the Coronaviridae family: SARS-CoV-2 [1]. As of 7 August 2021, the Johns Hopkins University and the WHO have reported that SARS-CoV-2 has infected more than 200 million individuals worldwide with more than 4.2 million deaths attributed to COVID-19 [2,3]. In order to contain the pandemic, global research has mobilized rapidly, resulting in new advances in basic and clinical research, mainly in the development of vaccines that may prevent infection by SARS-CoV-2 and the mortality associated with COVID-19 disease [4,5]. Multiple vaccine candidates have undergone emergency use clearance among different countries, leading to more than 4.3 billion vaccine doses administered worldwide up to 7 August 2021 [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
